

(1112)



# U.S. Environmental Protection Agency Integrated Risk Information System

[Recent Additions](#) | [Contact Us](#) | [Print Version](#) Search:

[EPA Home](#) > [Browse EPA Topics](#) > [Human Health](#) > [Health Effects](#) > [IRIS Home](#) > [IRIS Summaries](#)

Full IRIS Summary     [QuickView](#)

[List of IRIS Substances](#)

## Acenaphthene (CASRN 83-32-9)

[view Quick View](#)

### MAIN CONTENTS

0442

#### Acenaphthene; CASRN 83-32-9

Health assessment information on a chemical substance is included in IRIS only after a comprehensive review of chronic toxicity data by U.S. EPA health scientists from several Program Offices and the Office of Research and Development. The summaries presented in Sections I and II represent a consensus reached in the review process. Background information and explanations of the methods used to derive the values given in IRIS are provided in the Background Documents.

STATUS OF DATA FOR Acenaphthene

**File First On-Line 11/01/1990**

Category (section)	Status	Last Revised
Oral RfD Assessment (I.A.)	on-line	04/01/1994
Inhalation RfC Assessment (I.B.)	no data	
Carcinogenicity Assessment (II.)	no data	05/01/1993

### I. Chronic Health Hazard Assessments for Noncarcinogenic Effects

#### I.A. Reference Dose for Chronic Oral Exposure (RfD)

Substance Name -- Acenaphthene  
CASRN -- 83-32-9  
Last Revised -- 04/01/1994

The oral Reference Dose (RfD) is based on the assumption that thresholds exist for certain toxic effects such as cellular necrosis. It is expressed in units of mg/kg-day. In general, the RfD is an estimate (with uncertainty spanning perhaps an order of magnitude) of a daily exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a lifetime. Please refer to the Background Document for an elaboration of these concepts. RfDs can also be derived for the noncarcinogenic health effects of

**Chronic Health Hazard for Non-Carcinogenic Effects**

**Reference Dose for Chronic Oral Exposure (RfD)**

- [Oral RfD Summary](#)
- [Principal and Supporting Studies](#)
- [Uncertainty and Modifying Factors](#)
- [Additional Studies/Comments](#)
- [Confidence in the Oral RfD](#)
- [EPA Documentation and Review](#)

**Reference Concentration for Chronic Inhalation Exposure (RfC)**

- [Inhalation RfC Summary](#)
- [Principal and Supporting Studies](#)
- [Uncertainty and Modifying Factors](#)
- [Additional Studies/Comments](#)
- [Confidence in the Inhalation RfC](#)
- [EPA Documentation and Review](#)

**Carcinogenicity Assessment for Lifetime Exposure**

**Evidence for Human Carcinogenicity**

- [Weight-of-Evidence Characterization](#)
- [Human Carcinogenicity Data](#)
- [Animal Carcinogenicity Data](#)
- [Supporting Data for Carcinogenicity](#)

**Quantitative Estimate of**



9928

elaboration of these concepts. RfDs can also be derived for the noncarcinogenic health effects of substances that are also carcinogens. Therefore, it is essential to refer to other sources of information concerning the carcinogenicity of this substance. If the U.S. EPA has evaluated this substance for potential human carcinogenicity, a summary of that evaluation will be contained in Section II of this file.

### I.A.1. Oral RfD Summary

Critical Effect	Experimental Doses*	UF	MF	RfD
Hepatotoxicity	NOAEL: 175 mg/kg/day	3000	1	6E-2 mg/kg/day
Mouse Oral Subchronic Study	LOAEL: 350 mg/kg/day			
U.S. EPA, 1989				

\*Conversion Factors: None

### I.A.2. Principal and Supporting Studies (Oral RfD)

U.S. EPA. 1989. Mouse oral subchronic study with acenaphthene. Study conducted by Hazelton Laboratories, Inc., for the Office of Solid Waste, Washington, DC.

Four groups of CD-1 mice (20/sex/group) were gavaged daily with 0, 175, 350, or 700 mg/kg/day acenaphthene for 90 days. The toxicological evaluations of this study included body weight changes, food consumption, mortality, clinical pathological evaluations (including hematology and clinical chemistry), organ weights and histopathological evaluations of target organs. The results of this study indicated no treatment-related effects on survival, clinical signs, body weight changes, total food intake, and ophthalmological alterations. Liver weight changes accompanied by microscopic alterations (cellular hypertrophy) were noted in both mid- and high-dose animals and seemed to be dose-dependent. Additionally, high-dose males and mid- and high-dose females showed significant increases in cholesterol levels. Although increased liver weights, without accompanying microscopic alterations or increased cholesterol levels, were also observed at the low dose, this change was considered to be adaptive and was not considered adverse. The LOAEL is 350 mg/kg/day based on hepatotoxicity; the NOAEL is 175 mg/kg/day.

### I.A.3. Uncertainty and Modifying Factors (Oral RfD)

UF -- An uncertainty factor of 3000 reflects 10 each for inter- and intraspecies variability, 10 for the use of a subchronic study for chronic RfD derivation, and 3 for the lack of adequate data in a second species and reproductive/developmental data.

MF -- None

### I.A.4. Additional Studies/Comments (Oral RfD)

Reshetyuk et al. (1970) examined the comparative toxicity of acenaphthene and acenaphthylene with respect to naphthalene. On intraperitoneal administration in rats (species/number/sex unspecified), naphthalene was more toxic than acenaphthene and acenaphthylene. Two LD50? values (0.6 and 1.7 g/kg) were reported, but it is unclear to which of the three chemicals these values belonged. Intraperitoneal and intratracheal administration of naphthalene, acenaphthene, and acenaphthylene produced monotypic effects in the form of vascular disorders, and degeneration in the internal organs and central nervous system. Inflammatory changes were also observed in the lungs; the degree was the same for all three substances. Splenic degeneration was noted among the unscheduled deaths in this study. Reshetyuk et al. (1970) concluded that chronic inhalation of acenaphthene and acenaphthylene had more pronounced toxic effects than naphthalene.

[Quantitative Estimate of Carcinogenic Risk from Oral Exposure](#)

- [Summary of Risk Estimates](#)  
- [Dose-Response Data](#)  
- [Additional Comments](#)  
- [Discussion of Confidence](#)

[Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure](#)

- [Summary of Risk Estimates](#)  
- [Dose-Response Data](#)  
- [Additional Comments](#)  
- [Discussion of Confidence](#)

[EPA Documentation, Review and, Contacts](#)

[Bibliography](#)  
[Research History](#)  
[Synonyms](#)

Gershbein (1975) exposed partially hepatectomized rats to 15 mg/kg acenaphthene in the diet for 7 days. The only parameters used to assess toxicity were body weight, absolute liver weight, and liver regeneration. Information on histopathologic alterations and food intake is needed to evaluate the adversity of decreased body weight gain and increased liver weight observed in this study. Increased liver regeneration was reported. Because of its inherent deficiencies, this study is not considered adequate for RfD derivation.

Knobloch et al. (1969) administered 2 g/kg acenaphthene orally to rats and mice for 32 days. Weight loss and mild histopathological alterations in the liver and kidney were observed. It is unclear whether experimental controls were used.

#### **\_\_ I.A.5. Confidence in the Oral RfD**

Study -- Low  
Database -- Low  
RfD -- Low

Confidence in the study is low, because the observed effects were adaptive and not considered adverse. Confidence in the data base is low because of the lack of supporting chronic toxicity and developmental/reproductive studies. Low confidence in the RfD follows.

#### **\_\_ I.A.6. EPA Documentation and Review of the Oral RfD**

Source Document -- This assessment is not presented in any existing U.S. EPA document.

Other EPA Documentation -- U.S. EPA, 1980

Agency Work Group Review -- 11/15/1989

Verification Date -- 11/15/1989

#### **\_\_ I.A.7. EPA Contacts (Oral RfD)**

Please contact the IRIS Hotline for all questions concerning this assessment or IRIS, in general, at (301)345-2870 (phone), (301)345-2876 (FAX) or [Hotline.IRIS@epamail.epa.gov](mailto:Hotline.IRIS@epamail.epa.gov) (internet address).

[Back to top](#)

---

### **\_\_ I.B. Reference Concentration for Chronic Inhalation Exposure (RfC)**

Substance Name -- Acenaphthene  
CASRN -- 83-32-9

Not available at this time.

[Back to top](#)

---

## **\_\_ II. Carcinogenicity Assessment for Lifetime Exposure**

Substance Name -- Acenaphthene  
CASRN -- 83-32-9

Not available at this time.

[Back to top](#)

- \_III. [reserved]**
- \_IV. [reserved]**
- \_V. [reserved]**

**\_VI. Bibliography**

Substance Name -- Acenaphthene  
CASRN -- 83-32-9  
Last Revised -- 11/01/1990

**\_VI.A. Oral RfD References**

Gershbein, L.L. 1975. Liver regeneration as influenced by the structure of aromatic and heterocyclic compounds. Res. Commun. Chem. Pathol. Pharmacol. 11: 445.

Knobloch, K., S. Szendzikowski and A. Slusarczyk-Zalobona. 1969. Acute and subacute toxicity of acenaphthene and acenaphthylene. Med. Pracy. 20: 210-222. (Pol.) (Cited in U.S. EPA, 1980)

Reshetyuk, A.L, E.I. Talakina and P.A. En'yakova. 1970. Toxicological evaluation of acenaphthene and acenaphthylene. Gig. Tr. Prof. Zabol. 14: 46-47.

U.S. EPA. 1980. Ambient Water Quality Criteria Document for Acenaphthene. Prepared by the Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office, Cincinnati, OH for the Office of Water Regulation and Standards, Washington, DC. EPA-440/5-80-015. NTIS PB81-117269.

U.S. EPA. 1989. Mouse Oral Subchronic Study with Acenaphthene. Study conducted by Hazelton Laboratories, Inc., for the Office of Solid Waste, Washington, DC.

[Back to top](#)

**\_VI.B. Inhalation RfC References**

None

[Back to top](#)

**\_VI.C. Carcinogenicity Assessment References**

None

[Back to top](#)

**\_VII. Revision History**

Substance Name -- Acenaphthene  
CASRN -- 83-32-9

Date	Section	Description
11/01/1990	I.A.	Oral RfD summary on-line
11/01/1990	VI.	Bibliography on-line
01/01/1992	IV.	Regulatory Action section on-line
07/01/1992	IV.	Wrong information removed
05/01/1993	II.	Carcinogenicity assessment under review
08/01/1995	II.	EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
04/01/1997	III., IV., V.	Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.

[Back to top](#)

## VIII. Synonyms

Substance Name -- Acenaphthene  
CASRN -- 83-32-9  
Last Revised -- 11/01/1990

83-32-9  
Acenaphthylene, 1,2-dihydro-  
Acenaphthene  
HSDB 2659  
Naphthyleneethylene  
NSC 7657  
PERI-ETHYLENENAPHTHALENE  
1,2-DIHYDROACENAPHTHYLENE  
1,8-ETHYLENENAPHTHALENE

[Back to top](#)

[What's New](#) | [Search IRIS](#) | [IRIS Home](#) | [NCEA Home](#) | [ORD Home](#)

[EPA Home](#) | [Privacy and Security Notice](#) | [Contact Us](#)

Last updated on Thursday, September 19th, 2002  
URL: <http://www.epa.gov/iris/subst/0442.htm>